New monthly shot could ease Sjögren's dry mouth

NCT ID NCT07621809

Recruiting now Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This phase 3 study tests whether ianalumab, given as a monthly injection, can reduce dry mouth and other symptoms in people with Sjögren's disease who have a high symptom burden. About 570 adults will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug improves mouth dryness compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ianalumab (VAY736)
What this could lead to: If it works, this could provide a new monthly injection to significantly reduce dry mouth and other Sjögren's symptoms.
What could go wrong: This is a phase 3 trial, but results are not yet known. The drug may not improve symptoms more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJÖGREN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease Fatigue Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJÖGREN'S DISEASE

Contacts and locations

Locations

Accurate Clinical Research
RECRUITING

League City, Texas, 77573, United States
On Site Clinical Solutions Llc
RECRUITING

Charlotte, North Carolina, 28202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.